Long-term follow-up of patients with ANCA-associated vasculitis

Caroline Heijl

Long-term follow-up of patients with ANCA-associated vasculitis

Forskningsoutput: Avhandling › Doktorsavhandling (sammanläggning)

474 Nedladdningar (Pure)

Sammanfattning

Bibliographical note: Här klistrar du in följande text:
Defence details
Date: [yyyy-mm-dd]
Time: [hh:mm]
Place: [text without newline or tabs]
External reviewer(s)
Name: [surname, first name]
Title: [text without newline or tabs]
Affiliation: [text without newline or tabs]
---
ISSN: 1652-8220
Lund University, Faculty of Medicine Doctoral Dissertation Series 2017:??

Originalspråk	engelska
Kvalifikation	Doktor
Tilldelande institution	Institutionen för kliniska vetenskaper, Lund
Handledare	Höglund, Peter, handledare Westman, Kerstin, handledare Mohammad, Aladdin, handledare
Tilldelningsdatum	2017 maj 19
Utgivningsort	Lund
Förlag	Lund University, Faculty of Medicine
ISBN (tryckt)	978-91-7619-441-6
Status	Published - 2017

Bibliografisk information

Bibliographical note:
Defence details
Date: 2017-05-19
Time: 13:00
Place: Segerfalksalen, BMC, Lund University
External reviewer(s)
Name: Stegmayr, Bernd
Title: Professor
Affiliation: Umeå University
---
ISSN: 1652-8220
Lund University, Faculty of Medicine Doctoral Dissertation Series 2017:61

FN:s Globala mål

Denna forskningsoutput relaterar till följande Globala mål

SDG 3 – God hälsa och välbefinnande

Ämnesklassifikation (UKÄ)

Medicin och hälsovetenskap

Fria nyckelord

Anca-associated vasculitis

Tillgång till dokument

Long-term follow-up of patients with ANCA-associated vasculitisPublicerad version, 2,54 MB

Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials.
Heijl, C., Harper, L., Flossmann, O., Stücker, I., Scott, D., Watts, R. A., Höglund, P., Westman, K. & Mahr, A., 2011, I: Annals of the Rheumatic Diseases. 70, s. 1415-1421
Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review
Long-term patient survival in ANCA-associated vasculitis
Flossmann, O., Berden, A., de Groot, K., Hagen, C., Harper, L., Heijl, C., Höglund, P., Jayne, D., Luqmani, R., Mahr, A., Mukhtyar, C., Pusey, C., Rasmussen, N., Stegeman, C., Walsh, M. & Westman, K., 2011, I: Annals of the Rheumatic Diseases. 70, 3, s. 488-494
Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

Citera det här

@phdthesis{93c550df4b8a43768613f47cd2f09d8e,

title = "Long-term follow-up of patients with ANCA-associated vasculitis",

abstract = "This thesis is based on long-term follow-up results from two cohorts of patients with ANCA-associated vasculitis; one cohort with 535 patients originally included in 4 European randomized clinical trials (papers I and II) and one Swedish population-based cohort including 195 patients (papers III and IV). Two areas are covered in the two cohorts, respectively; the assessment of mortality, prognostic factors and causes of death in the two cohorts (paper I and III) and the assessment of malignancy risk compared with a matched general population (papers II and IV). Results Paper I: 1-, 2-, and 5-year survival was 88\%, 85\% and 78\%. Predictors of death were age, gender, kidney function and disease activity at presentation. Main causes of death were active vasculitis and infection during the first year, and after the first year, malignancy and cardiovascular disease. Paper II: Higher risk for malignancy at all sites and non-melanoma skin cancer. Paper III: 1-, 2-, 5-, and 10-year survival was 87\%, 82\%, 70\% and 55\%, respectively. Predictors of death were age, gender, kidney function and organ involvement at diagnosis. Main causes of death were active vasculitis and infection during the first year, and after the first year, malignancy and cardiovascular disease. Paper IV: Higher risk for malignancy at all sites, non-melanoma skin cancer, bladder cancer and pancreatic cancer. Conclusions: The mortality and malignancy risks in patients treated for AAV with current treatment protocols are higher than in the general population. However, the mortality in the group of patients with AAV without gastrointestinal, cardiovascular, or renal involvement at presentation is not significantly increased compared with the general population. ",

keywords = "Anca-associated vasculitis",

author = "Caroline Heijl",

note = "Defence details Date: 2017-05-19 Time: 13:00 Place: Segerfalksalen, Biomedicinskt centrum (BMC), S{\"o}lvegatan 17, Lund. External reviewer(s) Name: Stegmayr, Bernd Title: professor Affiliation: Ume{\aa} University --- ISSN: 1652-8220 Lund University, Faculty of Medicine Doctoral Dissertation Series 2017:61",

year = "2017",

language = "English",

isbn = "978-91-7619-441-6",

publisher = "Lund University, Faculty of Medicine",

type = "Doctoral Thesis (compilation)",

school = "Department of Clinical Sciences, Lund",

}

TY - THES

T1 - Long-term follow-up of patients with ANCA-associated vasculitis

AU - Heijl, Caroline

N1 - Defence details Date: 2017-05-19 Time: 13:00 Place: Segerfalksalen, Biomedicinskt centrum (BMC), Sölvegatan 17, Lund. External reviewer(s) Name: Stegmayr, Bernd Title: professor Affiliation: Umeå University --- ISSN: 1652-8220 Lund University, Faculty of Medicine Doctoral Dissertation Series 2017:61

PY - 2017

Y1 - 2017

N2 - This thesis is based on long-term follow-up results from two cohorts of patients with ANCA-associated vasculitis; one cohort with 535 patients originally included in 4 European randomized clinical trials (papers I and II) and one Swedish population-based cohort including 195 patients (papers III and IV). Two areas are covered in the two cohorts, respectively; the assessment of mortality, prognostic factors and causes of death in the two cohorts (paper I and III) and the assessment of malignancy risk compared with a matched general population (papers II and IV). Results Paper I: 1-, 2-, and 5-year survival was 88%, 85% and 78%. Predictors of death were age, gender, kidney function and disease activity at presentation. Main causes of death were active vasculitis and infection during the first year, and after the first year, malignancy and cardiovascular disease. Paper II: Higher risk for malignancy at all sites and non-melanoma skin cancer. Paper III: 1-, 2-, 5-, and 10-year survival was 87%, 82%, 70% and 55%, respectively. Predictors of death were age, gender, kidney function and organ involvement at diagnosis. Main causes of death were active vasculitis and infection during the first year, and after the first year, malignancy and cardiovascular disease. Paper IV: Higher risk for malignancy at all sites, non-melanoma skin cancer, bladder cancer and pancreatic cancer. Conclusions: The mortality and malignancy risks in patients treated for AAV with current treatment protocols are higher than in the general population. However, the mortality in the group of patients with AAV without gastrointestinal, cardiovascular, or renal involvement at presentation is not significantly increased compared with the general population.

AB - This thesis is based on long-term follow-up results from two cohorts of patients with ANCA-associated vasculitis; one cohort with 535 patients originally included in 4 European randomized clinical trials (papers I and II) and one Swedish population-based cohort including 195 patients (papers III and IV). Two areas are covered in the two cohorts, respectively; the assessment of mortality, prognostic factors and causes of death in the two cohorts (paper I and III) and the assessment of malignancy risk compared with a matched general population (papers II and IV). Results Paper I: 1-, 2-, and 5-year survival was 88%, 85% and 78%. Predictors of death were age, gender, kidney function and disease activity at presentation. Main causes of death were active vasculitis and infection during the first year, and after the first year, malignancy and cardiovascular disease. Paper II: Higher risk for malignancy at all sites and non-melanoma skin cancer. Paper III: 1-, 2-, 5-, and 10-year survival was 87%, 82%, 70% and 55%, respectively. Predictors of death were age, gender, kidney function and organ involvement at diagnosis. Main causes of death were active vasculitis and infection during the first year, and after the first year, malignancy and cardiovascular disease. Paper IV: Higher risk for malignancy at all sites, non-melanoma skin cancer, bladder cancer and pancreatic cancer. Conclusions: The mortality and malignancy risks in patients treated for AAV with current treatment protocols are higher than in the general population. However, the mortality in the group of patients with AAV without gastrointestinal, cardiovascular, or renal involvement at presentation is not significantly increased compared with the general population.

KW - Anca-associated vasculitis

M3 - Doctoral Thesis (compilation)

SN - 978-91-7619-441-6

PB - Lund University, Faculty of Medicine

CY - Lund

ER -

Long-term follow-up of patients with ANCA-associated vasculitis

Sammanfattning

Bibliografisk information

FN:s Globala mål

Ämnesklassifikation (UKÄ)

Fria nyckelord

Tillgång till dokument

Fingeravtryck

Forskningsoutput

Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials.

Long-term patient survival in ANCA-associated vasculitis

Citera det här